Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway
A registry-based study
Bibliographic Data
| ID | 14905626 |
|---|---|
| Authors | Kristian Braathen Malme (0000-0002-8108-2110, University of Oslo, corresponding author), Kjersti Ulstein (Norwegian Labour and Welfare Administration), Ane-Kristine Finbråten, Ane‐Kristine Finbråten (0000-0003-2705-8010, Lovisenberg Diakonale Sykehus), Linda Elise Couëssurel Wüsthoff (0000-0002-6808-8323, Oslo University Hospital), Knut Boe Kielland (Innlandet Hospital Trust), Joakim Hauge (0000-0002-2989-412X, Innlandet Hospital Trust), Olav Dalgard (0000-0003-4470-3181, University of Oslo), Håvard Midgard (0000-0001-5043-5107, Oslo University Hospital) |
| Year | 2023 |
| Volume | 116 |
| Pages | 104044 |
| Publication date | 2023-06-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2023.104044 |
| PMID | 37149914 |
| OpenAlex | W4368340845 |
| Language | EN |
| Citations received | 4 |
| References cited | 40 |
Although HCV treatment uptake among PWID increased, strategies to improve treatment among women and individuals not engaged in OAT should be addressed
Cohort · Hepatitis C · Logistic regression · Demography · Hepatitis B Virus Studies · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · Medicine · Internal Medicine
Changes in Risk Behaviour Among People With Recent Injecting Drug Use in Oslo 2002–2024
Increases in Hepatitis C Virus (HCV) Treatment and Cure Among People Who Inject Drugs in the Seattle Area Between 2018 and 2022
Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs
Towards elimination of hepatitis C in Oslo
Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs
Global patterns of opioid use and dependence
Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Elimination of hepatitis C virus infection among people who use drugs
Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Hepatitis C Surveillance among Youth and Young Adults in New York City, 2009–2013
| Citations per year | 2 |
|---|---|
| Citation span | 2024 - 2026 (3) |
| Highly cited | No |